Oxford Biomedica signs LSA with Juno Therapeutics

19 Mar 2020

Cell and gene focused CDMO Oxford Biomedica (OXB) has signed a licence and clinical supply agreement which could be worth up to USD227 million with Juno Therapeutics, the firms announced Wednesday.

The agreement allows Juno Therapeutics – a Bristol Myers Squibb subsidiary -- to use OXB’s LentiVector platform for its CAR-T and TCR-T programmes in oncology and other indications while establishing an initial five-year clinical supply agreement.

Oxford Biomedica signs LSA with Juno Therapeutics

Under the terms of the LSA, OXB will receive USD10 million upfront in cash, a potential USD86 million dependent on it reaching certain development and regulatory milestones and a further $131 million in sales-based milestone payments and an undisclosed royalty on net sales of products developed using LentiVector.

OXB will also receive payments from process development and scale-up projects relating to the GMP manufacture of lentiviral vectors for use in clinical trials.

In return, Juno Therapeutics will also have access to OXB’s new 7,800 m2 commercial manufacturing centre OxBox, in Oxford, UK. OXB said it is already working on four undisclosed active projects, with Juno able to add projects in the future.

“This is the second company that has committed to working with us in our new OxBox facility, which we expect to be producing GMP vector by the end of the first half 2020,” said OXB chief executive John Dawson. “Today’s announcement further validates our decision taken in 2018 to invest in and scale up our GMP manufacturing facilities for clinical and commercial viral vector manufacture to support both existing and new partners and customers as well as the expected demand from industry.”

Related news

UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

3 Apr 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
Chinese CDMOs legislating for the future

Chinese CDMOs legislating for the future

2 Apr 2020

The Chinese pharmaceutical CDMO sector is set for rapid expansion, thanks to major amendments to the country's Drug Administration Law that make outsourcing manufacturing easier

Read more 
FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials on Tuesd...

Read more 
New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
Cambrex names Troy Player as head of early stage development and testing

Cambrex names Troy Player as head of early stage development and testing

31 Mar 2020

Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.

Read more 
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

31 Mar 2020

The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.

Read more 
EMA to only issue electronic medicines certificates during COVID-19 pandemic

EMA to only issue electronic medicines certificates during COVID-19 pandemic

30 Mar 2020

The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...

Read more 
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

30 Mar 2020

Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.

Read more 
New device offers a convenient way to monitor compressed air for viable particles

New device offers a convenient way to monitor compressed air for viable particles

30 Mar 2020

Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.

Read more